Heineken warned British pubs and bars that GLP-1 weight-loss drugs could put pressure on beer and cider sales, according to a company presentation seen by Reuters. Sent to hospitality customers in October 2026, the presentation said the drugs can reduce the desire to drink and warned that “fullness and fewer serves” could make traditional multi-pint drinking occasions harder to sustain, Reuters reported.
The brewer advised venues to promote half-pints, low- and no-alcohol drinks and pair drinks with small plates, warning that visits and spending could otherwise decline. Heineken told Reuters the presentation was part of its regular engagement with UK hospitality businesses. The company said it was seeing some changes in consumption among GLP-1 users, but added that they were not abandoning alcohol altogether. Instead, it said, users were increasingly choosing smaller serves, lower-alcohol drinks and more premium products.
What the spending data shows
Reuters cited Circana’s tracking of a group of US households with a GLP-1 user between 2024 and 2026. After two years on the drugs, those households spent about 7% less per month on alcohol than households without a user, including around 13.5% less on beer. That US household spending comparison does not measure sales at British pubs.
The possible effect on beer remains contested. Carlsberg told Reuters that existing data did not yet show GLP-1 drugs were a clear driver of beer consumption trends.
Comments